It was also found that adropin may play an important role in the pathophysiology of non-alcoholic fatty liver disease (NAFLD) (Sayin et al., 2014; Kutlu et al., 2019; Chen et al., 2020b). Here, ENHO is linked to metabolic dysfunction-associated steatotic liver disease.